The First Affiliated Hospital of Soochow University: clinical-trial pipeline
The First Affiliated Hospital of Soochow University is the sponsor of 258 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 128 are not yet finished and 1 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 99 |
| Phase 2 | 74 |
| Phase 3 | 21 |
| Phase 1/2 | 17 |
| Phase 1 | 15 |
| Phase 2/3 | 14 |
| Phase 4 | 13 |
| Early phase 1 | 5 |
Trials by status
| Status | Trials |
|---|---|
| Unknown | 94 |
| Recruiting | 88 |
| Completed | 31 |
| Not yet recruiting | 29 |
| Active, not recruiting | 11 |
| Withdrawn or not authorised | 3 |
| Suspended or halted | 1 |
| Terminated | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 177 |
| Immunology and rheumatology | 40 |
| Haematology | 23 |
| Cardiovascular | 16 |
| Rare and genetic diseases | 12 |
| Gastroenterology and liver | 9 |
| Infectious disease and vaccines | 9 |
| Dermatology | 2 |
| Nephrology and urology | 2 |
| Neurology | 2 |
| Respiratory | 2 |
| Women's health and obstetrics | 2 |
Countries
| Country | Trials |
|---|---|
| China | 238 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-02 | New trial posted | BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute L… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT07662382 | Cousin vs. Sibling Donors in Haplo-HSCT | Not applicable | Not yet recruiting | China |
| NCT07511426 | U96-CAR-T-Cells For R/R B-ALL | Phase 1 | Not yet recruiting | China |
| NCT06559644 | Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia | Early phase 1 | Not yet recruiting | China |
| NCT07599423 | A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse… | Phase 2 | Not yet recruiting | China |
| NCT07612319 | Romiplostim for Oral TPO-RA Resistant ITP | Not applicable | Recruiting | China |
| NCT07655674 | Endofaster Robot for Gastroesophageal Submucosal Tumors: A Randomized Controlled Study | Not applicable | Not yet recruiting | |
| NCT06548958 | A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic… | Not applicable | Recruiting | China |
| NCT07463651 | MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib | Phase 3 | Recruiting | China |
| NCT07652138 | Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma | Phase 1 | Recruiting | China |
| NCT06816134 | Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute L… | Phase 2 | Recruiting | China |
| NCT06486337 | CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma | Phase 2 | Recruiting | China |
| NCT07666568 | Younger vs. Older Donors in Allo-HSCT: TTE | Not applicable | Not yet recruiting | China |
| NCT03196414 | Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory… | Phase 1/2 | Recruiting | China |
| NCT07688759 | CMV-CMI in csCMVi After HSCT | Not applicable | Recruiting | China |
| NCT05571774 | Construction of a Database for TTP | Not applicable | Recruiting | China |
| NCT07206823 | Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primar… | Not applicable | Recruiting | China |
| NCT06468943 | Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | Phase 2 | Recruiting | China |
| NCT03984968 | CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia | Phase 1/2 | Active, not recruiting | China |
| NCT07074496 | Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Dia… | Early phase 1 | Recruiting | China |
| NCT05805098 | Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML | Phase 2/3 | Recruiting | China |
| NCT05931757 | A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL | Phase 2 | Not yet recruiting | China |
| NCT07672262 | VA Consolidation in Intermediate-Risk AML | Phase 2 | Recruiting | China |
| NCT07622849 | FMT in Transplant-related Gastrointestinal Mucositis | Not applicable | Recruiting | China |
| NCT07499284 | A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia | Not applicable | Recruiting | China |
| NCT06682416 | The Impact of Local Anesthetic Solution Temperature on Epidural-related Maternal Fever | Not applicable | Recruiting | China |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "The First Affiliated Hospital of Soochow University clinical trials: 128 open, 35 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/the-first-affiliated-hospital-of-soochow-university/, data as of 2026-10-25.